ALDH1 Cancer Stem Cell Marker as a Prognostic Factor in Triple-Negative Breast Cancer

Abstract EN

Breast cancer is the most common cancer with an increasing incidence in Asia.

About 20% of all breast cancers are triple-negative breast cancers (TNBCs).

BCSC is a subset of tumor cells that has stem cell-like characteristics, such as a high capacity for self-renewal and tumor initiation, which implies that BCSC may cause aggressiveness of TNBC.

ALDH1 has a role in early stem cell differentiation through its function in the oxidation of retinol to retinoic acid, proposed to be a strong candidate for breast cancer stem cells.

Various studies have shown that ALDH1 is one of the markers of CSC that can be used as a prognosis indicator because it can be a biological marker for poor prognostic factors in TNBC.

This study assessed the prognostic survival rate with a retrospective cohort method in TNBC patients.

A total of 54 of 55 patients treated at RSCM were tested for the expression of ALDH1 through an immunohistochemistry assay of breast cancer tissue using ALDH1 staining.

Survival analysis was done to obtain the prognostic data of ALDH1.

Positive ALDH1 expression was obtained at 38.89% in TNBC patients.

One-year survival and three years of survival in TNBC patients with positive ALDH1 expression were 42.9% and 33.3%, respectively.

In this study, ALDH1 can be used as a poor survival prognostic factor with HR 2.636 and p value 0.013.

The conclusion of this study is that ALDH1 can be used as a poor prognostic factor in TNBC patients although it cannot be an independent prognostic factor.